FBXW7 Targets the SPT6-ΔNp63 Axis for Degradation to Inhibit Esophageal Tumorigenesis Induced by 4-Nitroquinoline N-Oxide

Abstract

FBXW7 (F-box and WD repeat domain-containing 7) is a classic tumor suppressor that promotes ubiquitylation and degradation of various oncoproteins. Although its tumor suppressor role in many types of cancers has been established, whether and how FBXW7 regulates in vivo esophageal tumorigenesis was previously unknown. Here, we report, using genetically modified mouse models, that Fbxw7 inhibits esophageal tumorigenesis induced by the carcinogen 4NQO (4-nitroquinoline N-oxide), but not by Pik3Ca^E545K (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), a frequently mutated gene in human esophageal squamous cell carcinoma (ESCC). Mechanistically, FBXW7 depletion causes the accumulation of SPT6 (suppressor of Ty6), a transcriptional elongation factor, which is a novel substrate of FBXW7. SPT6 acts as a transcriptional co-activator of ΔNp63, which is also a substrate of FBXW7 in ESCC cells. Both SPT6 and ΔNp63, accumulated upon FBXW7 knockdown, contribute to the proliferation of ESCC cells. In clinical human ESCC tissues, the protein levels of SPT6 and FBXW7 are inversely correlated, and high SPT6 levels with low FBXW7 levels predict poorer patient survival. Collectively, FBXW7 acts as a tumor suppressor in ESCC by promoting the degradation of both SPT6 and ΔNp63, and the SPT6-ΔNp63 axis may serve as a therapeutic target for ESCC.

Keywords

chemical carcinogenesis / esophageal squamous cell carcinoma / FBXW7 E3 ligase / suppressor of Ty6 / ΔNp63

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[2] W. Chen, R. Zheng, P. D. Baade, et al., “Cancer Statistics in China, 2015,” CA: A Cancer Journal for Clinicians 66, no. 2 (2016): 115–132.

[3] Z. Liu, Y. Zhao, P. Kong, et al., “Integrated Multi-Omics Profiling Yields a Clinically Relevant Molecular Classification for Esophageal Squamous Cell Carcinoma,” Cancer Cell 41, no. 1 (2023): 181-195, e9.

[4] Y. Cui, H. Chen, R. Xi, et al., “Whole-Genome Sequencing of 508 Patients Identifies Key Molecular Features Associated With Poor Prognosis in Esophageal Squamous Cell Carcinoma,” Cell Research 30, no. 10 (2020): 902–913.

[5] K. Yumimoto and K. I. Nakayama, “Recent Insight Into the Role of FBXW7 as a Tumor Suppressor,” Seminars in Cancer Biology 67, no. Pt 2 (2020): 1–15.

[6] R. J. Davis, M. Welcker, and B. E. Clurman, “Tumor Suppression by the Fbw7 Ubiquitin Ligase: Mechanisms and Opportunities,” Cancer Cell 26, no. 4 (2014): 455–464.

[7] P. Nash, X. Tang, S. Orlicky, et al., “Multisite Phosphorylation of a CDK Inhibitor Sets a Threshold for the Onset of DNA Replication,” Nature 414, no. 6863 (2001): 514–521.

[8] S. Akhoondi, D. Sun, N. von der Lehr, et al., “FBXW7/hCDC4 is a General Tumor Suppressor in Human Cancer,” Cancer Research 67, no. 19 (2007): 9006–9012.

[9] Q. Zhang, D. Karnak, M. Tan, T. S. Lawrence, M. A. Morgan, and Y. Sun, “FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4,” Molecular Cell 61, no. 3 (2016): 419–433.

[10] H. Lan, M. Tan, Q. Zhang, et al., “LSD1 destabilizes FBXW7 and Abrogates FBXW7 Functions Independent of Its Demethylase Activity,” PNAS 116, no. 25 (2019): 12311–12320.

[11] J. E. Grim, S. E. Knoblaugh, K. A. Guthrie, et al., “Fbw7 and p53 Cooperatively Suppress Advanced and Chromosomally Unstable Intestinal Cancer,” Molecular and Cellular Biology 32, no. 11 (2012): 2160–2167.

[12] R. Sancho, A. Jandke, H. Davis, M. E. Diefenbacher, I. Tomlinson, and A. Behrens, “F-Box and WD Repeat Domain-Containing 7 Regulates Intestinal Cell Lineage Commitment and Is a Haploinsufficient Tumor Suppressor,” Gastroenterology 139, no. 3 (2010): 929–941.

[13] Q. Zhang, Y. Zhang, J. D. Parsels, et al., “Fbxw7 Deletion Accelerates Kras(G12D)-Driven Pancreatic Tumorigenesis via Yap Accumulation,” Neoplasia 18, no. 11 (2016): 666–673.

[14] M. Levine and R. Tjian, “Transcription Regulation and Animal Diversity,” Nature 424, no. 6945 (2003): 147–151.

[15] A. Shilatifard, W. S. Lane, K. W. Jackson, R. C. Conaway, and J. W. Conaway, “An RNA Polymerase II Elongation Factor Encoded by the Human ELL Gene,” Science 271, no. 5257 (1996): 1873–1876.

[16] Y. Aoi and A. Shilatifard, “Transcriptional Elongation Control in Developmental Gene Expression, Aging, and Disease,” Molecular Cell 83, no. 22 (2023): 3972–3999.

[17] C. L. W. Miller, J. L. Warner, and F. Winston, “Insights Into Spt6: A Histone Chaperone That Functions in Transcription, DNA Replication, and Genome Stability,” Trends in Genetics 39, no. 11 (2023): 858–872.

[18] C. Diao, P. Guo, W. Yang, et al., “SPT6 Recruits SND1 to Co-Activate Human Telomerase Reverse Transcriptase to Promote Colon Cancer Progression,” Molecular Oncology 15, no. 4 (2021): 1180–1202.

[19] E. A. A. Obara, D. Aguilar-Morante, R. D. Rasmussen, et al., “SPT6-Driven Error-Free DNA Repair Safeguards Genomic Stability of Glioblastoma Cancer Stem-Like Cells,” Nature Communications 11, no. 1 (2020): 4709.

[20] J. Li, X. Xu, M. Tiwari, et al., “SPT6 Promotes Epidermal Differentiation and Blockade of an Intestinal-Like Phenotype Through Control of Transcriptional Elongation,” Nature Communications 12, no. 1 (2021): 784.

[21] A. B. Truong, M. Kretz, T. W. Ridky, R. Kimmel, and P. A. Khavari, “p63 regulates Proliferation and Differentiation of Developmentally Mature Keratinocytes,” Genes & development 20, no. 22 (2006): 3185–3197.

[22] G. Melino, “p63 is a Suppressor of Tumorigenesis and Metastasis Interacting With Mutant p53,” Cell Death and Differentiation 18, no. 9 (2011): 1487–1499.

[23] X. Guo, W. M. Keyes, C. Papazoglu, et al., “TAp63 induces Senescence and Suppresses Tumorigenesis In Vivo,” Nature Cell Biology 11, no. 12 (2009): 1451–1457.

[24] Y. Xu, X. Yang, Q. Xiong, J. Han, and Q. Zhu, “The Dual Role of p63 in Cancer,” Frontiers in Oncology 13 (2023): 1116061.

[25] Y. Li, S. Giovannini, T. Wang, et al., “p63: A Crucial Player in Epithelial Stemness Regulation,” Oncogene 42, no. 46 (2023): 3371–3384.

[26] N. Thurfjell, P. J. Coates, T. Uusitalo, et al., “Complex p63 mRNA Isoform Expression Patterns in Squamous Cell Carcinoma of the Head and Neck,” International Journal of Oncology 25, no. 1 (2004): 27–35.

[27] A. Yang, R. Schweitzer, D. Sun, et al., “p63 is Essential for Regenerative Proliferation in Limb, Craniofacial and Epithelial Development,” Nature 398, no. 6729 (1999): 714–718.

[28] P. P. Massion, P. M. Taflan, S. M. Jamshedur Rahman, et al., “Significance of p63 Amplification and Overexpression in Lung Cancer Development and Prognosis,” Cancer Research 63, no. 21 (2003): 7113–7121.

[29] A. Patel, L. F. Garcia, V. Mannella, et al., “Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma,” Cancer Research 80, no. 12 (2020): 2676–2688.

[30] F. Galli, M. Rossi, Y. D'Alessandra, et al., “MDM2 and Fbw7 Cooperate to Induce p63 Protein Degradation Following DNA Damage and Cell Differentiation,” Journal of Cell Science 123, no. Pt 14 (2010): 2423–2433.

[31] X. H. Tang, B. Knudsen, D. Bemis, S. Tickoo, and L. J. Gudas, “Oral Cavity and Esophageal Carcinogenesis Modeled in Carcinogen-Treated Mice,” Clinical Cancer Research 10, no. 1 Pt 1 (2004): 301–313.

[32] A. Ohkoshi, T. Suzuki, M. Ono, T. Kobayashi, and M. Yamamoto, “Roles of Keap1-Nrf2 System in Upper Aerodigestive Tract Carcinogenesis,” Cancer Prevention Research 6, no. 2 (2013): 149–159.

[33] Z. Wang, H. Inuzuka, J. Zhong, et al., “Tumor Suppressor Functions of FBW7 in Cancer Development and Progression,” FEBS Letters 586, no. 10 (2012): 1409–1418.

[34] M. Welcker and B. E. Clurman, “FBW7 Ubiquitin Ligase: A Tumour Suppressor at the Crossroads of Cell Division, Growth and Differentiation,” Nature Reviews Cancer 8, no. 2 (2008): 83–93.

[35] Y. Song, L. Li, Y. Ou, et al., “Identification of Genomic Alterations in Oesophageal Squamous Cell Cancer,” Nature 509, no. 7498 (2014): 91–95.

[36] D. C. Lin, J. J. Hao, Y. Nagata, et al., “Genomic and Molecular Characterization of Esophageal Squamous Cell Carcinoma,” Nature Genetics 46, no. 5 (2014): 467–473.

[37] A. Roy, J. Skibo, F. Kalume, et al., “Mouse Models of human PIK3CA-Related Brain Overgrowth Have Acutely Treatable Epilepsy,” Elife 4 (2015): e12703.

[38] B. J. Thompson, V. Jankovic, J. Gao, et al., “Control of Hematopoietic Stem Cell Quiescence by the E3 Ubiquitin Ligase Fbw7,” Journal of Experimental Medicine 205, no. 6 (2008): 1395–1408.

[39] H. Nakagawa, T. C. Wang, L. Zukerberg, et al., “The Targeting of the Cyclin D1 Oncogene by an Epstein–Barr Virus Promoter in Transgenic Mice Causes Dysplasia in the Tongue, Esophagus and Forestomach,” Oncogene 14, no. 10 (1997): 1185–1190.

[40] T. A. Soucy, P. G. Smith, M. A. Milhollen, et al., “An Inhibitor of NEDD8-Activating Enzyme as a New Approach to Treat Cancer,” Nature 458, no. 7239 (2009): 732–736.

[41] J. Fan, M. Bellon, M. Ju, et al., “Clinical Significance of FBXW7 Loss of Function in Human Cancers,” Molecular Cancer 21, no. 1 (2022): 87.

[42] L. Yin, J. Zhang, and Y. Sun, “Early Growth Response-1 Is a New Substrate of the GSK3beta-FBXW7 Axis,” Neoplasia 34 (2022): 100839.

[43] C. Ruptier, A. De Gasperis, S. Ansieau, et al., “TP63 P2 promoter Functional Analysis Identifies Beta-Catenin as a Key Regulator of DeltaNp63 Expression,” Oncogene 30, no. 46 (2011): 4656–4665.

[44] C. Yu, H. Tang, Y. Guo, et al., “Hot Tea Consumption and Its Interactions with Alcohol and Tobacco Use on the Risk for Esophageal Cancer: A Population-Based Cohort Study,” Annals of Internal Medicine 168, no. 7 (2018): 489–497.

[45] Collaborators GBDOC. "The Global, Regional, and National Burden of Oesophageal Cancer and Its Attributable Risk Factors in 195 Countries and territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017," Lancet Gastroenterol Hepatol 5, no. 6 (2020): 582–597.

[46] Y. Pan, J. Liu, Y. Gao, et al., “FBXW7 Loss of Function Promotes Esophageal Squamous Cell Carcinoma Progression via Elevating MAP4 and ERK Phosphorylation,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 75.

[47] G. Fronza, P. Campomenosi, R. Iannone, and A. Abbondandolo, “The 4-Nitroquinoline 1-Oxide Mutational Spectrum in Single Stranded DNA Is Characterized by Guanine to Pyrimidine Transversions,” Nucleic Acids Research 20, no. 6 (1992): 1283–1287.

[48] D. Kanojia and M. M. Vaidya, “4-Nitroquinoline-1-Oxide Induced Experimental Oral Carcinogenesis,” Oral Oncology 42, no. 7 (2006): 655–667.

[49] D. Ramotar, E. Belanger, I. Brodeur, J. Y. Masson, and E. A. Drobetsky, “A Yeast Homologue of the human Phosphotyrosyl Phosphatase Activator PTPA Is Implicated in Protection Against Oxidative DNA Damage Induced by the Model Carcinogen 4-Nitroquinoline 1-Oxide,” Journal of Biological Chemistry 273, no. 34 (1998): 21489–21496.

[50] Z. Liu, R. Su, A. Ahsan, et al., “Esophageal Squamous Cancer From 4NQO-Induced Mice Model: CNV Alterations,” International Journal of Molecular Sciences 23, no. 22 (2022): 14304.

[51] A. A. Leystra, D. A. Deming, C. D. Zahm, et al., “Mice Expressing Activated PI3K Rapidly Develop Advanced Colon Cancer,” Cancer Research 72, no. 12 (2012): 2931–2936.

[52] D. S. Meyer, S. Koren, C. Leroy, et al., “Expression of PIK3CA Mutant E545K in the Mammary Gland Induces Heterogeneous Tumors but Is Less Potent Than Mutant H1047R,” Oncogenesis 2, no. 9 (2013): e74.

[53] V. F. Merino, S. Cho, X. Liang, et al., “Inhibitors of STAT3, Beta-Catenin, and IGF-1R Sensitize Mouse PIK3CA-Mutant Breast Cancer to PI3K Inhibitors,” Molecular Oncology 11, no. 5 (2017): 552–566.

[54] S. M. Doris, J. Chuang, O. Viktorovskaya, et al., “Spt6 Is Required for the Fidelity of Promoter Selection,” Molecular Cell 72, no. 4 (2018): 687-699, e6.

[55] L. Yin, J. Zhang, Z. Zhu, et al., “The FBXW7-KMT2 Axis in Cancer-Associated Fibroblasts Controls Tumor Growth via an Epigenetic-Paracrine Mechanism,” Proceedings National Academy of Science USA 122, no. 13 (2025): e2423130122.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.